Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kyoung Hwa Koo"'
Supplementary Figure 3 from MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4990b9c82f291ce16e157bda307644
https://doi.org/10.1158/0008-5472.22388877.v1
https://doi.org/10.1158/0008-5472.22388877.v1
Supplementary Figure 2 from MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::693562c883fb7100270e4c232867a2cf
https://doi.org/10.1158/0008-5472.22388880.v1
https://doi.org/10.1158/0008-5472.22388880.v1
Publikováno v:
Cancer Research. 71:445-453
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) are used widely to treat metastatic colorectal cancer (mCRC) patients, but it is now clear that patients harboring K-ras mutation are resistant to EGFR mAbs such as cetuximab (Erbitu
Publikováno v:
Oncotarget
// Kyoung-Hwa Koo 1,2 , Woo-Jeong Jeong 1,2 , Yong-Hee Cho 1,2 , Jong-Chan Park 1,2 , Do Sik Min 1,3 and Kang-Yell Choi 1,2 1 Translational Research Center for Protein Function Control, Yonsei University, Seoul, Korea 2 Department of Biotechnology, C
Autor:
Ki Sung Hong, Man Ryul Lee, Wha Ja Cho, Kye Seong Kim, Jun Ho Lee, Jong Soo Kim, Jeong Min Shin, Kyoung Hwa Koo, Jeong Woo Park
Publikováno v:
Molecules and cells. 28(6)
Previously, we have reported tissue- and stage-specific expression of miR-372 in human embryonic stem cells and so far, not many reports speculate the function of this microRNA (miRNA). In this study, we screened various human cancer cell lines inclu
Publikováno v:
Cancer Research. 71:1734-1734
EGFR monoclonal antibodies (mAbs) are used widely to treat metastatic colorectal cancer (mCRC) patients, but it is now clear that patients harboring K-ras mutation are resistant to EGFR mAbs such as cetuximab (Erbitux) and panitumumab (Vectibix). For